Overview

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen